Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes | Zendy

Jennifer B. Green | Zendy; M. Angelyn Bethel | Zendy; Paul W. Armstrong | Zendy; John B. Buse | Zendy; Samuel S. Engel | Zendy; Jyotsna Garg | Zendy; Robert Josse | Zendy; Keith D. Kaufman | Zendy; Joerg Koglin | Zendy; Russell Scott | Zendy; John M. Lachin | Zendy; Darren K. McGuire | Zendy; Michael Pencina | Zendy; Eberhard Standl | Zendy; Peter P. Stein | Zendy; Shailaja Suryawanshi | Zendy; Frans Van de Werf | Zendy; Eric D. Peterson | Zendy; Rury R. Holman | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes

Author(s) -

Jennifer B. Green,

M. Angelyn Bethel,

Paul W. Armstrong,

John B. Buse,

Samuel S. Engel,

Jyotsna Garg,

Robert Josse,

Keith D. Kaufman,

Joerg Koglin,

Russell Scott,

John M. Lachin,

Darren K. McGuire,

Michael Pencina,

Eberhard Standl,

Peter P. Stein,

Shailaja Suryawanshi,

Frans Van de Werf,

Eric D. Peterson,

Rury R. Holman

Publication year - 2015

Publication title -

new england journal of medicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 19.889

H-Index - 1030

eISSN - 1533-4406

pISSN - 0028-4793

DOI - 10.1056/nejmoa1501352

Subject(s) - sitagliptin , medicine , semaglutide , placebo , hazard ratio , sitagliptin phosphate , myocardial infarction , glycated hemoglobin , alogliptin , glycemic , type 2 diabetes , relative risk , confidence interval , diabetes mellitus , dipeptidyl peptidase 4 inhibitor , heart failure , endocrinology , insulin , liraglutide , alternative medicine , pathology

Data are lacking on the long-term effect on cardiovascular events of adding sitagliptin, a dipeptidyl peptidase 4 inhibitor, to usual care in patients with type 2 diabetes and cardiovascular disease.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research